The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Abstract
Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has been highly pursued by many academic laboratories and pharmaceutical companies as a promising strategy for cancer therapy. To date, based on the explanation of the cocrystal structure of MDM2 with p53, many highly potent and selective small-molecule MDM2 inhibitors have been successfully discovered and nine of them are currently under different clinical trials for cancer therapy. Herein, we will review the function of MDM2 and provide a comprehensive and updated overview of small-molecule MDM2 inhibitors in different clinical phases for cancer therapy, especially focusing on the identification and optimization, and preclinical/clinical studies of these clinical-stage MDM2 inhibitors. Challenges regarding acquired resistance and potential toxicity of MDM2 inhibitors to normal tissues and outlook are also briefly discussed, which will further guide the design of new small-molecule MDM2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, long-term administration of an MDM2 inhibitor may induce acquired resistance related to TP53 mutations and increased MDMX expression.574,575”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [575]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Self-citationMDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Self-citationp300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
Self-citationLi, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312
Self-citationThe p53 family in differentiation and tumorigenesis
Stiewe, T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2072 · Cited by 306
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Self-citationSun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290
MDM2 promotes ubiquitination and degradation of MDMX
Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211
Self-citationHolzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
Liao, G., Yang, D., Ma, L., Li, W., Hu, L., Zeng, L., Wu, P., Duan, L., & Liu, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.044 · Cited by 63
Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63
Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54
Zhuang, C., Miao, Z., Wu, Y., Guo, Z., Li, J., Yao, J., Xing, C., Sheng, C., & Zhang, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401800k · Cited by 50
Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26064 · Cited by 36
Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29
Research works printed but not linked: 79
- Bieging, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, 14, 359, 10.1038/nrc3711 · DOI · Paper page
- Vousden, 2002, Live or let die: the cell's response to p53, Nat. Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
- Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
- Wu, 1997, Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene, Mol. Med., 3, 441, 10.1007/BF03401691 · DOI · Paper page
- Wu, 1993, The p53-mdm-2 autoregulatory feedback loop, Genes Dev., 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
- Freedman, 1999, Functions of the MDM2 oncoprotein, Cell. Mol. Life Sci., 55, 96, 10.1007/s000180050273 · DOI · Paper page
- Juven-Gershon, 1999, Mdm2: the ups and downs, Mol. Med., 5, 71, 10.1007/BF03402141 · DOI · Paper page
- Bond, 2005, MDM2 is a central node in the p53 pathway: 12 years and counting, Curr. Cancer Drug Targets, 5, 3, 10.2174/1568009053332627 · DOI · Paper page
- Capoulade, 1998, Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells, Oncogene, 16, 1603, 10.1038/sj.onc.1201702 · DOI
- Prives, 1999, The p53 pathway, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
- Fuller, 2009, Predicting druggable binding sites at the protein-protein interface, Drug Discov. Today, 14, 155, 10.1016/j.drudis.2008.10.009 · DOI · Paper page
- Zak, 2013, Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present), Expert Opin. Ther. Pat., 23, 425, 10.1517/13543776.2013.765405 · DOI
- Wang, 2012, Small molecule agents targeting the p53-MDM2 pathway for cancer therapy, Med. Res. Rev., 32, 1159, 10.1002/med.20236 · DOI
- Khoury, 2011, The p53-MDM2/MDMX axis - a chemotype perspective, MedChemComm, 2, 246, 10.1039/c0md00248h · DOI
- Popowicz, 2011, The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious, Angew. Chem., 50, 2680, 10.1002/anie.201003863 · DOI · Paper page
- Tisato, 2017, MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer, J. Hematol. Oncol., 10, 133, 10.1186/s13045-017-0500-5 · DOI · Paper page
- Vu, 2013, Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development, ACS Med. Chem. Lett., 4, 466, 10.1021/ml4000657 · DOI · Paper page
- Tovar, 2013, MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models, Cancer Res., 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
- Hoffman-Luca, 2015, Elucidation of acquired resistance to Bcl-2 and MDM2 inhibitors in acute leukemia in vitro and in vivo, Clin. Cancer Res., 21, 2558, 10.1158/1078-0432.CCR-14-2506 · DOI · Paper page
- Bauer, 2018, A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L), J. Clin. Oncol., 36, 11514, 10.1200/JCO.2018.36.15_suppl.11514 · DOI
- Yi, 2018, A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma, J. Exp. Clin. Cancer Res., 37, 97, 10.1186/s13046-018-0765-8 · DOI · Paper page
- Valat, 2014, Abstract 1798: mechanistic study of NVP-CGM097: a potent, selective and species specific inhibitor of p53-Mdm2, Cancer Res., 74, 1798, 10.1158/1538-7445.AM2014-1798 · DOI
- Furet, 2016, Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument, Bioorg. Med. Chem. Lett, 26, 4837, 10.1016/j.bmcl.2016.08.010 · DOI · Paper page
- Ferretti, 2016, Abstract 1224: insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials, Cancer Res., 76, 1224, 10.1158/1538-7445.AM2016-1224 · DOI
- Reutershan, 2021, Discovery of MK-4688: an efficient inhibitor of the HDM2–p53 protein–protein interaction, J. Med. Chem., 64, 16213, 10.1021/acs.jmedchem.1c01524 · DOI
- Wade, 2013, MDM2, MDMX and p53 in oncogenesis and cancer therapy, Nat. Rev. Cancer, 13, 83, 10.1038/nrc3430 · DOI · Paper page
- Riedinger, 2009, Inhibitors of MDM2 and MDMX: a structural perspective, Future Med. Chem., 1, 1075, 10.4155/fmc.09.75 · DOI
- Millard, 2011, Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update, Curr. Pharmaceut. Des., 17, 536, 10.2174/138161211795222649 · DOI
- Lane, 2010, p53-based cancer therapy, Cold Spring Harbor Perspect. Biol., 2, 10.1101/cshperspect.a001222 · DOI · Paper page
- Dickens, 2010, Small-molecule inhibitors of MDM2 as new anticancer therapeutics, Semin. Cancer Biol., 20, 10, 10.1016/j.semcancer.2009.10.003 · DOI
- Khoo, 2014, Drugging the p53 pathway: understanding the route to clinical efficacy, Nat. Rev. Drug Discov., 13, 217, 10.1038/nrd4236 · DOI · Paper page
- Liu, 2019, The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy, Eur. J. Med. Chem., 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI
- Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
- Wang, 2021, FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application, Eur. J. Med. Chem., 214, 10.1016/j.ejmech.2021.113218 · DOI
- Wang, 2021, Discovery of the triazolo[1,5-a]pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance, J. Med. Chem., 64, 16187, 10.1021/acs.jmedchem.1c01498 · DOI
- Wang, 2020, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators, J. Med. Chem., 63, 15979, 10.1021/acs.jmedchem.0c01741 · DOI
- Wang, 2019, Development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1–UBC12 protein–protein interaction, J. Med. Chem., 62, 2772, 10.1021/acs.jmedchem.9b00113 · DOI
- Lu, 2020, Drug repurposing: discovery of troxipide analogs as potent antitumor agents, Eur. J. Med. Chem., 202, 10.1016/j.ejmech.2020.112471 · DOI
- Wang, 2020, Asymmetric catalysis in synthetic strategies for chiral benzothiazepines, Green Synthesis Catalys., 1, 12, 10.1016/j.gresc.2020.05.005 · doi:10.1016/j.gresc.2020.05.005
- Tang, 2020, Asymmetric catalytic hydrogenation of imines and enamines in natural product synthesis, Green Synthesis Catalys., 1, 26, 10.1016/j.gresc.2020.05.006 · doi:10.1016/j.gresc.2020.05.006
- Yang, 2021, Carbon dioxide cycle via electrocatalysis: electrochemical carboxylation of CO2 and decarboxylative functionalization of carboxylic acids, Green Synthesis Catalys., 2, 19, 10.1016/j.gresc.2021.01.009 · DOI
- Yan, 2021, Harnessing noncovalent interaction of chalcogen bond in organocatalysis: from the catalyst point of view, Green Synthesis Catalys., 2, 329, 10.1016/j.gresc.2021.08.002 · doi:10.1016/j.gresc.2021.08.002
- Picksley, 1993, The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?, Bioessays : News Rev. Mol. Cellular Dev. Biol., 15, 689, 10.1002/bies.950151008 · DOI · Paper page
- Fang, 2000, Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53, J. Biol. Chem., 275, 8945, 10.1074/jbc.275.12.8945 · DOI · Paper page
- Kubbutat, 1998, Regulation of Mdm2-directed degradation by the C terminus of p53, Mol. Cell Biol., 18, 5690, 10.1128/MCB.18.10.5690 · DOI · Paper page
- Lai, 2001, Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization, J. Biol. Chem., 276, 31357, 10.1074/jbc.M011517200 · DOI · Paper page
- Grossman, 2003, Polyubiquitination of p53 by a ubiquitin ligase activity of p300, Science, 300, 342, 10.1126/science.1080386 · DOI · Paper page
- Chen, 1993, Mapping of the p53 and mdm-2 interaction domains, Mol. Cell Biol., 13, 4107
- Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
- Lai, 2000, Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length, Arch. Biochem. Biophys., 381, 278, 10.1006/abbi.2000.1998 · DOI
- Dumaz, 1999, Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2, EMBO J., 18, 7002, 10.1093/emboj/18.24.7002 · DOI · Paper page
- Maya, 2001, ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage, Genes Dev., 15, 1067, 10.1101/gad.886901 · DOI · Paper page
- Tao, 1999, P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2, Proc. Natl. Acad. Sci. U.S.A., 96, 6937, 10.1073/pnas.96.12.6937 · DOI · Paper page
- Weber, 1999, Nucleolar Arf sequesters Mdm2 and activates p53, Nat. Cell Biol., 1, 20, 10.1038/8991 · DOI · Paper page
- Gu, 2002, Mutual dependence of MDM2 and MDMX in their functional inactivation of p53, J. Biol. Chem., 277, 19251, 10.1074/jbc.C200150200 · DOI · Paper page
- Lohrum, 2003, Regulation of HDM2 activity by the ribosomal protein L11, Cancer Cell, 3, 577, 10.1016/S1535-6108(03)00134-X · DOI · Paper page
- Mayo, 2001, A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus, Proc. Natl. Acad. Sci. U.S.A., 98, 11598, 10.1073/pnas.181181198 · DOI · Paper page
- Gottlieb, 2002, Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis, Oncogene, 21, 1299, 10.1038/sj.onc.1205181 · DOI · Paper page
- Zhou, 2001, HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation, Nat. Cell Biol., 3, 973, 10.1038/ncb1101-973 · DOI · Paper page
- Freeman, 2003, PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms, Cancer Cell, 3, 117, 10.1016/S1535-6108(03)00021-7 · DOI · Paper page
- Popowicz, 2010, Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery, Cell Cycle, 9, 1104, 10.4161/cc.9.6.10956 · DOI · Paper page
- Chen, 2014, Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists, J. Med. Chem., 57, 4962, 10.1021/jm401798r · DOI
- Zhao, 2013, A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice, J. Med. Chem., 56, 5553, 10.1021/jm4005708 · DOI · Paper page
- Aguilar, 2014, Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles, J. Med. Chem., 57, 10486, 10.1021/jm501541j · DOI
- Rew, 2012, Structure-based design of novel inhibitors of the MDM2–p53 interaction, J. Med. Chem., 55, 4936, 10.1021/jm300354j · DOI · Paper page
- Ye, 2015, Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation, Xenobiotica, 45, 681, 10.3109/00498254.2015.1010632 · DOI
- Gessier, 2015, Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode, Bioorg. Med. Chem. Lett, 25, 3621, 10.1016/j.bmcl.2015.06.058 · DOI
- Stachyra-Valat, 2016, Abstract 1239: NVP-HDM201: biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2, Cancer Res., 76, 1239, 10.1158/1538-7445.AM2016-1239 · DOI · Paper page
- Holzer, 2016, Discovery of NVP-HDM201-first disclosure of a next-generation Mdm2 inhibitor with superior characteristics, Cancer Res., 76, 4855, 10.1158/1538-7445.AM2016-4855 · DOI
- Ravandi, 2016, A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML), Leuk. Res., 48, 92, 10.1016/j.leukres.2016.07.004 · DOI · Paper page
- Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 · DOI · Paper page
- Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, Drug Resist. Updates, 27, 14, 10.1016/j.drup.2016.05.001 · DOI · Paper page
- Dong, 2020, Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update, Drug Resist. Updates, 49, 10.1016/j.drup.2020.100681 · DOI · Paper page
- Wang, 2020, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators, J. Med. Chem., 63, 15979, 10.1021/acs.jmedchem.0c01741 · DOI
- Ng, 2018, Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models, Nat. Commun., 9, 2024, 10.1038/s41467-018-04356-9 · DOI
- Wurz, 2019, Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors, J. Med. Chem., 62, 445, 10.1021/acs.jmedchem.8b01945 · DOI
- Wang, 2021, Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries, Eur. J. Med. Chem., 219, 113425, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
- Uy, 2020, Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia, Invest. N. Drugs, 38, 1430, 10.1007/s10637-020-00907-4 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
“The development of new MDM2 ‒ p53 PPI inhibitors, the construction of dual inhibitors targeting MDM2 and MDMX, the combination of drugs, the use of molecular glue technology, and the development of MDM2 ‒ PROTAC degraders are possible solutions to this issue 72,73 .”
BackgroundSmall-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259
Metadata
- Authors
- Wang, S., & Chen, F.-E.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 236
- Pages
- 114334
- ISSN
- 0223-5234
- Cited by
- 92
- References
- 39
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Shanghai Municipal Natural Science Foundation (13ZR1402200)
- China Association for Science and Technology (2017QNRC061)
- National Natural Science Foundation of China (21372050, 22077018)
- Fudan University (JIH1615060)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.